BS outcomes have improved over the last 20 years, thanks to earlier and more aggressive treatment strategies. However, vascular involvement and CNS problems are areas that still need better treatments. We hope our center will play an important role in helping BS patients, not only in the U.S. but also across the globe.
Acknowledgments
I would like to thank all the research assistants and other personnel who have helped me over the years in getting our center started; it would not have been possible without them.
Dr. Yazici is Assistant Professor of Medicine at NYU School of Medicine and director of the Seligman Center for Advanced Therapeutics and Behçet’s Syndrome Evaluation, Treatment and Research Center.
Disclosures
Dr. Yazici is a consultant/speaker for Bristol–Myers Squibb, Celgene, Centocor, Genentech, Pfizer, Roche, and UCB.
References
- Behçet H. Uber rezidivierende, aphthose, dürch ein Virus verursachte Geshwure am Munde, am Auge und an den Genitalien. Dematologische Wochenschrift 1937;36:1152-1157.
- Moses Alder N, Fisher M, Yazici Y. Behçet’s syndrome patients have high levels of functional disability, fatigue and pain as measured by a Multi-dimensional Health Assessment Questionnaire (MDHAQ). Clin Exp Rheumatol. 2008;26(4 Suppl 50):110-113.
- Hatemi G, Fresko I, Tascilar K, et al. Enthesopathy is increased among Behçet’s syndrome patients with acne and arthritis: An ultrasonographic study. Arthritis Rheum. 2008;58:1539-1545.
- Tunc R, Saip S, Siva A, et al. Cerebral venous thrombosis is associated with major vessel disease in Behçet’s syndrome. Ann Rheum Dis. 2004;63:1693-1694.
- Hatemi G, Bahar H, Uysal S, et al. The pustular skin lesions in Behçet’s syndrome are not sterile. Ann Rheum Dis. 2004;63:1450-1452.
- International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335:1078-1080.
- Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behçet syndrome: A 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003;82:60-76.
- Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behçet’s disease: Report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2008;67:1656-1662.
- Yazici Y, Schimmel E, Swearingen C. Behçet’s syndrome in the US: Clinical characteristics, treatment and ethnic/racial differences in manifestation in 347 patients with BS. Arthritis Rheum. 2009, presented at 2009 ACR meeting.
